Published on November 17, 2009 at 7:07 AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it is offering to sell, subject to market and other conditions, 5,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering.
BioCryst also intends to grant the underwriters a 30-day option to purchase up to an aggregate of 750,000 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by BioCryst. Morgan Stanley will be acting as the sole book-runner for the offering, with JMP Securities and Oppenheimer & Co. acting as co-managers.
SOURCE BioCryst Pharmaceuticals, Inc.